Autres langues Molecular Partners AG Nasdaq

Actions

MOLN

US60853G1067

Marché Fermé - Nasdaq Autres places de cotation 22:30:00 03/05/2024			Varia. 5j.	Varia. 1 janv.
3,98 ^USD	+5,71%		+2,58%	-4,78%

29/04	Molecular Partners AG annonce la publication dans Cancer Immunology Research de données précliniques soutenant le mécanisme d'action proposé par le MP0533	CI
18/04	Principales informations avant-Bourse	AW

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Morning Briefing - Markt Schweiz	30/04
Molecular Partners mit positivem Expertenbericht zum Leukämie-Kandidat MP0533	29/04
Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533’s Proposed Mechanism of Action	29/04
Molecular Partners AG Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533's Proposed Mechanism of Action	29/04
Molecular Partners : Annual General Meeting Minutes	26/04
Life Science Cares Launches in Switzerland	19/04
Molecular Partners : statement regarding Passive Foreign Investment Company status	18/04
Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting	17/04
Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting	17/04
Morning Briefing - Markt Schweiz	17/04
Morning Briefing - Markt Schweiz	16/04
Morning Briefing - Markt Schweiz	15/04
Morning Briefing - Markt Schweiz	08/04
Court Dismisses Class Action Against Biopharmaceutical Company For Failing To Disclose Progress Of Competitor; Second Circuit Affirms Dismissal Of Putative Class Action Against Allergan; Eleventh Circuit Affirms That "Toxic" Lender Qualified As A "Dealer" Under The Exchange Act Due To High-Volume Trading; Delaware Court Of Chancery Invalidates Governance Rights In Stockholder Agreement	01/04
Molecular Partners Publishes Invitation to Annual General Meeting 2024	26/03
Molecular Partners Publishes Invitation to Annual General Meeting 2024	26/03
Molecular Partners : Einladung zur ordentlichen Generalversammlung 2024	21/03
Morning Briefing - Markt Schweiz	15/03
Molecular Partners Swings to Loss in FY23; Revenue Down	15/03
Molecular Partners sieht Finanzierung bis weit ins Jahr 2026 gesichert	14/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Molecular Partners AG Nasdaq

Actions

MOLN

US60853G1067

Autres langues

Filtres